FDA approves first generic estradiol/levonorgestrel weekly patch

Women with an intact uterus who are candidates for systemic menopausal hormone therapy (MHT) now have a generic, once-weekly combined estrogen-progestogen option, after the FDA approved the first generic version of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg).¹ The product, from Zydus Pharmaceuticals (USA) Inc, is therapeutically equivalent to the Bayer reference product.¹

"Menopause is a universal experience for women, and it can greatly affect a person's quality of life. This approval makes effective treatment more accessible," said Kyle Diamantas, JD, acting FDA commissioner.¹

Indications and dosing of generic estradiol/levonorgestrel patch

As with Climara Pro, the generic is indicated in women with an intact uterus for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause and for the prevention of postmenopausal osteoporosis.¹ The 22-cm² system contains 4.4 mg estradiol and 1.39 mg levonorgestrel and delivers a nominal 0.045 mg estradiol and 0.015 mg levonorgestrel daily.² It is applied once weekly to the lower abdomen, avoiding the breasts and the waistline.² When the goal is solely osteoporosis prevention, labeling advises considering nonestrogen medications first, and attempts to discontinue therapy are recommended at 3- to 6-month intervals.²

"Once-weekly dosing can make a real difference in how patients manage their care," said Michael Davis, MD, PhD, director of the FDA's Center for Drug Evaluation and Research. "A patch offers a convenient alternative to daily oral medications, which may help patients stay on track with their treatment."¹

Endometrial protection with combined transdermal MHT

Unlike the estrogen-only patches commonly used in menopause care, this system delivers estrogen and a progestogen in a single patch.¹ The levonorgestrel component is included to reduce the risk of endometrial hyperplasia that can occur with unopposed estrogen, which is why the product is limited to women with a uterus.¹ For these patients, a single weekly system avoids pairing an estrogen patch with a separate oral progestogen.

Menopausal VMS burden and MHT underuse

Menopause symptoms, including VMS, genitourinary changes, and bone loss, can substantially reduce quality of life and may persist for years.⁴ The 2022 Menopause Society (formerly NAMS) position statement affirms hormone therapy as the most effective treatment for VMS and genitourinary syndrome of menopause, notes its role in preventing bone loss and fracture, and recommends individualized risk stratification by age and time since menopause.³

Uptake remains low: according to the FDA, roughly 41 million US women were aged 45 to 64 years in 2020, but only about 2 million women aged 46 to 65 years received a hormone therapy prescription.⁴ The agency has also cited randomized data showing reduced all-cause mortality and fractures when MHT is started within 10 years of menopause onset, generally before age 60 years.⁴

The approval follows the FDA's February 2026 sign-off on the first labeling revisions removing cardiovascular disease, breast cancer, and probable dementia risk statements from MHT boxed warnings, a process initiated in November 2025 that spans systemic combination products.⁴

Contraindications and adverse reactions for estradiol/levonorgestrel patch

The generic and reference products are contraindicated in patients with undiagnosed abnormal genital bleeding; current or past breast cancer; estrogen-dependent neoplasia; active or prior deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease; hepatic impairment or disease; protein C, protein S, or antithrombin deficiency or other thrombophilic disorders; and known anaphylaxis, angioedema, or hypersensitivity to either component.¹

Adverse reactions occurring in at least 5% of patients include application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache, and flu syndrome.¹

Limitations and next steps for generic combined MHT

Generic approval does not add new efficacy or safety data or expand the reference product's indications; it establishes therapeutic equivalence to Climara Pro.¹ Only 1 dose strength is available, which limits dose titration within the product.² The FDA did not disclose pricing or launch timing and referred questions about availability to the manufacturer.¹ Whether generic entry broadens MHT use remains to be seen; prescribing should continue to weigh age, time since menopause, symptom severity, and thrombotic and cancer risk.³

References

1. US Food and Drug Administration. FDA approves once-weekly generic hormone therapy patch for women. News release. October 20, 2026. Accessed October 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women

2. Climara Pro (estradiol/levonorgestrel transdermal system). Prescribing information. Bayer HealthCare Pharmaceuticals Inc. Accessed October 20, 2026. https://www.drugs.com/pro/climara-pro.html

3. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028

4. US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. News release. February 12, 2026. Accessed October 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products